A nomogram for predicting metabolic-associated fatty liver disease in non-obese patients with newly diagnosed type 2 diabetes

Background Metabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent in non-obese patients with type 2 diabetes mellitus (T2DM) and leads to serious liver damage in this population. The study aims to develop and validate a nomogram to predict the risk of MAFLD in non-overweight individuals with newly diagnosed T2DM. Methods A total of 2372 non-obese (BMI < 25 kg/m² according to Chinese criteria) patients with newly diagnosed T2DM were enrolled and randomly assigned to the training and validation sets in a ratio of 7:3. The independent risk factors associated with MAFLD were screened by univariate and multivariate logistic regression, and a nomogram was constructed to predict the risk of MAFLD. Receiver operating characteristic curve (ROC), calibration curves, and decision curve analysis (DCA) were used to verify the performance and clinical utility of the model. Results Eight predictors, namely body mass index (BMI), alanine aminotransferase/aspartate aminotransferase (ALT/AST), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), fasting blood glucose (FBG), creatinine (Cr) and serum uric acid (SUA), were identified by multivariate logistic regression analysis from a total of 14 variables studied. The nomogram built using these seven predictors showed good prediction ability (AUC: 0.791 in the training cohort; AUC: 0.784 in the validation cohort), along with favorable calibration and clinical utility. Conclusion The nomogram demonstrated effectiveness as a screening tool for evaluating the risk of MAFLD in T2DM individuals without obesity, facilitating early identification and supporting enhanced management strategies for MAFLD.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-13
DOI
https://doi.org/10.3389/fendo.2026.1846441
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A nomogram for predicting metabolic-associated fatty liver disease in non-obese patients with newly diagnosed type 2 diabetes

石海燕, 成云云, Yuliang Cui, Tingting Li et al.
2 links
Frontiers in Endocrinology
Liver Disease Diagnosis and Treatment
article

A nomogram for predicting metabolic-associated fatty liver disease in non-obese patients with newly diagnosed type 2 diabetes

石海燕, 成云云, Yuliang Cui, Tingting Li, Fenghua Li, Wanjing Sun
article en

Abstract

Background Metabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent in non-obese patients with type 2 diabetes mellitus (T2DM) and leads to serious liver damage in this population. The study aims to develop and validate a nomogram to predict the risk of MAFLD in non-overweight individuals with newly diagnosed T2DM. Methods A total of 2372 non-obese (BMI < 25 kg/m² according to Chinese criteria) patients with newly diagnosed T2DM were enrolled and randomly assigned to the training and validation sets in a ratio of 7:3. The independent risk factors associated with MAFLD were screened by univariate and multivariate logistic regression, and a nomogram was constructed to predict the risk of MAFLD. Receiver operating characteristic curve (ROC), calibration curves, and decision curve analysis (DCA) were used to verify the performance and clinical utility of the model. Results Eight predictors, namely body mass index (BMI), alanine aminotransferase/aspartate aminotransferase (ALT/AST), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), fasting blood glucose (FBG), creatinine (Cr) and serum uric acid (SUA), were identified by multivariate logistic regression analysis from a total of 14 variables studied. The nomogram built using these seven predictors showed good prediction ability (AUC: 0.791 in the training cohort; AUC: 0.784 in the validation cohort), along with favorable calibration and clinical utility. Conclusion The nomogram demonstrated effectiveness as a screening tool for evaluating the risk of MAFLD in T2DM individuals without obesity, facilitating early identification and supporting enhanced management strategies for MAFLD.

Frontiers in EndocrinologyVol. 17
Qilu Hospital of Shandong University (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon